2 active not recruiting, 2 completed, 2 unknown, 1 not yet recruiting. 5 Phase 4, 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
Follow Pioglitazone 45 mg: new trials by email Literature Review of Pioglitazone 45 mg trials Research Report on Pioglitazone 45 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? Dapagliflozin (DAPA), Pioglitazone 45 mg, Placebo - Type 1 Diabetes | Phase 4 | Not yet recruiting | Dasman Diabetes Institute | 60 | 2025-09-15 | 2025-08-29 |
| The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia Pioglitazone 45 mg, Placebo - Lung Cancer | Phase 2 | Active not recruiting | Pennington Biomedical Research Center | 24 | 2024-01-03 | 2025-07-04 |
| The Role of Pioglitazone in Vascular Transcriptional Remodeling Pioglitazone 45 mg - Myocardial Reperfusion Injury | Phase 4 | Unknown | University of Campinas, Brazil | 20 | 2023-06-15 | 2024-01-12 |
| Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG - Type 2 Diabetes | Not applicable | Recruiting | Karolinska Institutet | 60 | 2023-02-08 | 2025-02-26 |
| Effect of Pioglitazone on T2DM Patients With COVID-19 Pioglitazone 45 mg - Covid19, Type 2 Diabetes | Phase 4 | Unknown | Dasman Diabetes Institute | 1506 | 2021-01-18 | 2021-03-17 |
| Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke Pioglitazone 45 mg, Placebo oral tablet - Stroke, Acute, Hyperglycemia | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-01 | 2022-09-15 |
| Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss - Nephrolithiasis, Uric Acid | Phase 4 | Completed | University of Texas Southwestern Medical Center | 29 | 2019-10-17 | 2026-08-31 |
| Dapagliflozin Plus Pioglitazone in T1DM Pioglitazone 45 mg, Placebo - Type 1 Diabetes Mellitus | Phase 4 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 120 | 2019-08-08 | 2026-07-29 |
| 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Boehringer Ingelheim | 936 | 2010-08-01 | 2014-10-20 |
Diabetes Mellitus, Type 2 (3) · Diabetes Mellitus, Type 1 (2) · COVID-19 (1) · Diabetes Mellitus (1) · Hyperglycemia (1) · Hypoglycemia (1) · Ketosis (1) · Lung Neoplasms (1) · Myocardial Reperfusion Injury (1) · Nephrolithiasis (1) · Stroke (1)
Dasman Diabetes Institute (2) · Boehringer Ingelheim (1) · Karolinska Institutet (1) · Milton S. Hershey Medical Center (1) · Pennington Biomedical Research Center (1) · The University of Texas Health Science Center at San Antonio (1) · University of Campinas, Brazil (1) · University of Texas Southwestern Medical Center (1)
United States (5) · Kuwait (3) · Qatar (2) · Brazil (1) · Estonia (1) · Germany (1) · Israel (1) · Latvia (1) · Saudi Arabia (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Andrei Sposito, Professor (1) · Fahd Al-Mulla, MD, PhD (1) · Fahd Al-Mulla, PhD (1) · Kerstin Bettermann, MD, PhD (1) · Khashayar Sakhaee, MD (1) · Mohamed Abu-Farha, PhD (1) · Mohamed Abu-farha (1) · Muhammed Abdul Ghani, MD, PhD (1) · Muhammed Abdul-Ghani, MD/PhD (1) · Thamer Alessa, MD (1)
2008 (1)